CVS Health said its retained share of rebates negotiated with drug makers this year comes to 2%, which translates to $300 million or 3% of the company’s annual earnings per share.
Amid Scrutiny, CVS Says Its PBM Retains Just 2% Of Drug Rebates
CVS Health said its retained share of rebates negotiated with drug makers this year comes to 2%, which translates to $300 million or 3% of the company’s annual earnings per share.